

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jay A. Goldstein, Michael Rothman, and Whe-Yong Lo

Serial No.: 10-691,928

Art Unit: 1616

Filed: October 23, 2003

Examiner: Not Yet Assigned

For: *ANTIFUNGAL FORMULATIONS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of the seventeen (17) documents cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,912,124	03-27-1990	Das, et al.	514/399
5,002,938	03-26-1991	Wang, et al.	514/171
5,021,458	06-04-1991	Maeda, et al.	514/655
5,110,809	05-05-1992	Wang, et al.	514/171
5,174,475	12-29-1992	Day, et al.	222/144.5

5,219,877	06-15-1993	Shah, et al.	514/399
5,310,545	05-10-1994	Eisen	424/49
5,407,663	04-18-1995	Eisen	424/49
6,075,056	06-13-2000	Quigley, Jr., et al.	514/649
6,080,744	06-27-2000	Ayon-Covarrubias	514/252

Publications

ADAMS, et al., "Perianal ulcerations from topical steroid use," *Cutis* 69(1): 67-68 (2002).

BARSKY, "Clinical comparison of desonide cream with fluocinonide cream in steroid-responsive dermatologic disorders," *Cutis* 18(6): 826-30 (1976).

FLEMING, et al., "An inflammatory eruption associated with recombinant human IL-6," *Brit. J. Dermatol.* 130(4): 534-40 (1994).

GREENBERG, et al., "Clotrimazole/betamethasone dipropionate: a review of costs and complications in the treatment of common cutaneous fungal infections," *Pediatr. Dermatol.* 19(1): 78-81 (2002).

JORIZZO, et al., "Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients," *J. Am. Acad. Dermatol.* 33(1): 74-7 (1995).


LUCKY, et al., "Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis," *Cutis* 59(3): 151-153 (1997).

WEINSTEIN & BERMAN, "Topical treatment of common superficial tinea infections," *Am. Fam. Physician* 65(10): 2095-2102 (2002).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,


Patrea L. Pabst
Reg. No. 31,284


Dated: February 25, 2004

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 10/691,928

Filed: October 23, 2003


INFORMATION DISCLOSURE STATEMENT




Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: February 25, 2004


Peggy Bailey

1716614_v1



4,912,124
5,002,938
5,021,458
5,110,809
5,174,475
5,219,877
5,310,545
5,407,663
6,075,056
6,080,744

ADAMS & SHETH, "Perianal ulcerations from topical steroid use," *Cutis* 69(1): 67-68 (2002).

BARSKY, "Clinical comparison of desonide cream with fluocinonide cream in steroid-responsive dermatologic disorders," *Cutis* 18(6): 826-30 (1976).

FLEMING, et al., "An inflammatory eruption associated with recombinant human IL-6," *Brit. J. Dermatol.* 130(4): 534-40 (1994).

GREENBERG, et al., "Clotrimazole/betamethasone dipropionate: a review of costs and complications in the treatment of common cutaneous fungal infections," *Pediatr. Dermatol.* 19(1): 78-81 (2002).

JORIZZO, et al., "Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients," *J. Am. Acad. Dermatol.* 33(1): 74-7 (1995).

LUCKY, et al., "Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis," *Cutis* 59(3): 151-153 (1997).


WEINSTEIN & BERMAN, "Topical treatment of common superficial tinea infections," *Am. Fam. Physician* 65(10): 2095-2102 (2002).

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/691,928
Filing Date	October 23, 2003
First Named Inventor	Jay A. Goldstein
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	JAG 100

Sheet	2	of	2
-------	---	----	---

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ADAMS, et al., "Perianal ulcerations from topical steroid use," <i>Cutis</i> 69(1): 67-68 (2002).	
		BARSKY, "Clinical comparison of desonide cream with fluocinonide cream in steroid-responsive dermatologic disorders," <i>Cutis</i> 18(6): 826-30 (1976).	
		FLEMING, et al., "An inflammatory eruption associated with recombinant human IL-6," <i>Brit. J. Dermatol.</i> 130(4): 534-40 (1994).	
		GREENBERG, et al., "Clotrimazole/betamethasone dipropionate: a review of costs and complications in the treatment of common cutaneous fungal infections," <i>Pediatr. Dermatol.</i> 19(1): 78-81 (2002).	
		JORIZZO, et al., "Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients," <i>J. Am. Acad. Dermatol.</i> 33(1): 74-7 (1995).	
		LUCKY, et al., "Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis," <i>Cutis</i> 59(3): 151-153 (1997).	
		WEINSTEIN & BERMAN, "Topical treatment of common superficial tinea infections," <i>Am. Fam. Physician</i> 65(10): 2095-2102 (2002).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+